חזרה לתוצאות החיפוש

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Generalized Myasthenia Gravis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Kristy Osgood) · kosgood@honorhealth.com
    Contact: Principal Investigator (Suraj Muley)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · 714-738-0800
    Contact: Principal Investigator (Jack H Florin)

  • SC3 Research Pasadena, Pasadena, California, United States

    Contact: Study coordinator (Charles Krinel) · Charles.krinel@neurosearch-usa.com
    Contact: Principal Investigator (M Lorraine Purino)

  • California Pacific Medical Center, Sacramento, California, United States

    Study coordinator · 415-600-3604
    Contact: Principal Investigator (Liberty Jenkins)

  • Neurology Offices Of South Florida, Boca Raton, Florida, United States

  • Superior Associates in Research LLC, Hialeah, Florida, United States

  • Augusta University Georgia, Augusta, Georgia, United States

    Contact: Study coordinator (Christian Ryan) · chrryan@augusta.edu · 706-721-6411
    Contact: Principal Investigator (Benjamin Barnes)

  • Hawaii Pacific Neuroscience LLC, Honolulu, Hawaii, United States

  • University of Chicago Medical Centr, Chicago, Illinois, United States

    Contact: Study coordinator (Deekshitha Turaka) · deekshitha.turaka@bsd.uchicago.edu · 773-702-6222
    Contact: Principal Investigator (Kourosh Rezania)

  • Prairie Heart Institute, Springfield, Illinois, United States

    Contact: Study coordinator (Megan Kaler) · mkaler@prairieresearch.com · 217-492-9100
    Contact: Principal Investigator (Raghav Govindarajan)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Principal Investigator (Jonathan Ross)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Principal Investigator (Amanda Guidon)

  • Henry Ford Health System, Detroit, Michigan, United States

    Study coordinator · 313-916-6781
    Contact: Principal Investigator (Kavita Grover)

  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Study coordinator (Kinjal Patel) · kinjal.patel@emory.edu
    Contact: Principal Investigator (Shruti Raja)

  • Neuroscience Research Ctr, Canton, Ohio, United States

  • Ohio State University Medical Center, Columbus, Ohio, United States

  • Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Thomas Keenan) · thomas.keenan@pennmedicine.upenn.edu · 215-662-8570
    Contact: Principal Investigator (Sami Khella)

  • Vanderbilt University Medical CenterX, Nashville, Tennessee, United States

    Contact: Principal Investigator (Amanda Peltier)

  • Nerve and Muscle Center of Texas, Houston, Texas, United States

    Contact: Study coordinator (Amy Megerle) · houneuamy@msn.com
    Contact: Principal Investigator (Aziz Shaibani.)

  • Central TX Neuro Consultants P A, Round Rock, Texas, United States

  • Center for Neurological Disorders G, Greenfield, Wisconsin, United States

    Contact: Study coordinator (Emily Barraza) · Emily.barraza@cndmilwaukee.com · 414-214-7275
    Contact: Principal Investigator (Bhupendra Khatri)

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Buenos Aires, Argentina

  • Novartis Investigative Site, Córdoba, Argentina

  • Novartis Investigative Site, Córdoba, Argentina

  • Novartis Investigative Site, Camperdown, Sydney, Australia

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Joinville, Santa Catarina, Brazil

  • Novartis Investigative Site, São Paulo, Brazil

  • Novartis Investigative Site, Hefei, Anhui, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shenzhen, Guangdong, China

  • Novartis Investigative Site, Shijiazhuang, Hebei, China

  • Novartis Investigative Site, Changsha, Hunan, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Nanchang, Jiangxi, China

  • Novartis Investigative Site, Xi'an, Shaanxi, China

  • Novartis Investigative Site, Xianyang, Shaanxi, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Fujian, China

  • Novartis Investigative Site, Jinan, China

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Limoges, Haute Vienne, France

  • Novartis Investigative Site, Garches, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Regensburg, Bavaria, Germany

  • Novartis Investigative Site, Würzburg, Bavaria, Germany

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Bochum, Germany

  • Novartis Investigative Site, Bochum, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Larissa, Greece

  • Novartis Investigative Site, Pátrai, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Florence, FI, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Palermo, PA, Italy

  • Novartis Investigative Site, Palermo, PA, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Orbassano, TO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Narita, Chiba, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site, Hanamaki, Iwate, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Higashi-Matsuyama, Saitama, Japan

  • Novartis Investigative Site, Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Warsaw, Masovian Voivodeship, Poland

  • Novartis Investigative Site, Krakow, POL, Poland

  • Novartis Investigative Site, Katowice, Silesian Voivodeship, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Vila Nova de Gaia, Portugal

  • Novartis Investigative Site, Belgrade, Serbia

  • Novartis Investigative Site, Niš, Serbia

  • Novartis Investigative Site, Daegu, South Korea

  • Novartis Investigative Site, Gwangju, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Alicante, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Inverness, Invernesshire, United Kingdom

  • Novartis Investigative Site, Ilford, London, United Kingdom

  • Novartis Investigative Site, Swinton, Manchester, United Kingdom

  • Novartis Investigative Site, Birmingham, West Midlands, United Kingdom

  • Novartis Investigative Site, Liverpool, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Southampton, United Kingdom

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)